Extrapulmonary pneumocystosis is a feature of severe immunosuppression which earlier reports have suggested is limited to patients receiving either no prophylaxis or aerosolised pentamidine. We report a case of disseminated pneumocystosis which developed in an HIV positive homosexual man despite systemic primary Pneumocystis carinii pneumonia prophylaxis.
Introduction
Pneumocystis carinii pneumonia (PCP) is the commonest severe opportunist infection seen in patients infected with the human immunodeficiency virus (HIV) .' This is despite effective prophylaxis which is now recommended for all patients with the acquired immunodeficiency syndrome (AIDS), those with CD4 count < 200/mm3, and those with symptomatic HIV disease.2 Patients with AIDS are now surviving longer3 and the complications of more severe immunosuppression are being seen. Amongst these is disseminated pneumocystosis. This report is the first, to our knowledge, to show that disseminated pneumocystosis can occur in patients receiving systemic PCP prophylaxis. (PCP) prophylaxis was started 18 months prior to his last admission, initially as fortnightly aerosolised pentamidine (300 mg via Respirgard II nebuliser) and then, after 11 months, changed to dapsone (100 mg twice weekly) and pyrimethamine (25 mg twice weekly). He claimed to be compliant with all medication. He had taken zidovudine for 1 year 3 years earlier but this had been stopped because of anaemia.
On examination he was pyrexial (40°C para-aortic lymph node. Stool, urine, blood and sputum cultures including mycobacterial culture were negative.
High dose co-trimoxazole (sulphamethoxazole 5.6 g and trimethoprim 1.12 g/24 h) and cefotaxime (2 g qds) were commenced intravenously. There was no significant improvement and 2 days later he deteriorated further with the sudden onset of left pleuritic chest pain, increasing hypoxia and dyspnoea. Two days later he developed a rash, sulphonamide allergy was suspected and so co-trimoxazole was discontinued and dapsone (100 mg od) orally and trimethoprim (15 mg/kg/24hrs) intravenously were substituted. In addition intravenous flucloxacillin (2g qds), ciprofloxacin (200 mg bd), and oral rifampicin (600 mg od), and pyrazinamide (1 g od) were added.
He deteriorated further with the spontaneous development of bilateral pneumothoraces. Neither CPAP nor mechanical ventilation were used. Bilateral intercostal drains were inserted but there was no improvement and he died 7 days later.
Post mortem examination revealed diffuse consolidation in both lungs and discrete haemorrhagic, necrotic lesions in the right lung unrelated to lymph nodes. The lungs showed the histological features of the proliferative (organising) phase of diffuse alveolar damage (adult respiratory distress syndrome) with a patchy chronic inflammatory infiltrate, interstitial oedema and prominent type II pneumocytes. Scattered foci of calcification of the alveolar exudate were present. In addition there were larger areas of confluent necrosis Discussion Extrapulmonary pneumocystosis occurs in up to 2-5% of AIDS patients,4 and several studies have shown that the diagnosis is often made post mortem.5 Earlier reports have suggested that systemic PCP prophylaxis confers protection.
In this case it may be that subclinical PCP was present prior to the introduction of systemic prophylaxis 7 months before his death. However, the lack of symptoms prior to this period suggest this is unlikely, particularly as primary prophylaxis with aerosolised pentamidine is effective. However, the effect of pentamidine in the severely immunocompromised with low CD4 counts has been questioned. Earlier reports have suggested that dapsone 100 mg and pyrimethamine 25 mg twice weekly are also effective in preventing PCP6 but recently at this dose dapsone and pyrimethamine have been shown to be less efficacious in preventing PCP than pentamidine or co-trimoxazole.7 Our experience would agree with this and we are currently studying data from our own unit.
Compliance in patients is a problem which is difficult to evaluate long term patient acceptability is important and is known to be higher with pentamidine than co-trimoxazole. 8 Extrapulmonary pneumocystosis is a problem among long-term survivors with AIDS. As the survival of patients with AIDS increases the frequency of disseminated pneumocystosis can be expected to increase. Both clinicians and pathologists are -becoming increasingly aware of disseminated pneumocystosis. As a result of earlier cases at both St. Mary's and Middlesex Hospitals9 we routinely look for evidence of pneumocysts in all clinical material from patients with HIV.
In conclusion, systemic prophylaxis with dapsone and pyrimethamine, a regimen now known to be less effective than co-trimoxazole in a patient with uncertain compliance, does not confer protection against the development of extrapulmonary PCP. We suggest that clinicians should be alert to this condition as early intervention may improve prognosis. 
